Lack of timely accrual information in oncology clinical trials: A cross-sectional analysis

Trials

Volumn 15, Issue 1, 2014, Pages

  Mitchell, Aaron P ^a,b   Hirsch, Bradford R ^a   Abernethy, Amy P ^a,c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Accrual; Cancer; Clinical trials; ClinicalTrials.gov; Renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; GOVERNMENT; HEALTH CARE SURVEY; HUMAN; INDUSTRY; KIDNEY CARCINOMA;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; KIDNEY NEOPLASMS; PATIENT SELECTION; REGISTRIES; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897417956     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-92     Document Type: Article

References (17)

1. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010, 16(22):5557-5563. 10.1158/1078-0432.CCR-10-0133, 3050630, 21062929.
2. Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 2010, 7(4):312-321. 10.1177/1740774510374973, 20595245.
3. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004, 291(22):2720-2726. 10.1001/jama.291.22.2720, 15187053.
4. Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, McCabe M, Kaplan R, Smith M, Ungerleider R, Christian MC. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002, 20(8):2109-2117. 10.1200/JCO.2002.08.056, 11956272.
5. Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, Wang XF, Sargent DJ, Wickerham DL, Cronin W, Djulbegovic B, Jr Slingluff CL. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res 2012, 18(1):256-262. 10.1158/1078-0432.CCR-11-1633, 21976533.
6. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, Elbourne DR, Francis D, Garcia J, Roberts I, Snowdon C. What influences recruitment to randomised controlled trials?. A review of trials funded by two UK funding agencies. Trials 2006, 7:9.
7. Carpenter WR, Weiner BJ, Kaluzny AD, Domino ME, Lee S-YD. The effects of managed care and competition on community-based clinical research. Med Care 2006, 44(7):671-679. 10.1097/01.mlr.0000220269.65196.72, 16799362.
8. Carpenter WR, Tyree S, Wu Y, Meyer AM, DiMartino L, Zullig L, Godley PA. A surveillance system for monitoring, public reporting, and improving minority access to cancer clinical trials. Clin Trials 2012, 9(4):426-435. 10.1177/1740774512449531, 3539770, 22761398.
9. Kanarek NF, Kanarek MS, Olatoye D, Carducci MA. Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study. Trials 2012, 13:237. 10.1186/1745-6215-13-237, 3551829, 23227880.
10. Tse T, Williams RJ, Zarin DA. Reporting 'basic results' in ClinicalTrials.gov. Chest 2009, 136(1):295-303. 10.1378/chest.08-3022, 2821287, 19584212.
11. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011, 16(Suppl 2):14-22. 3868199, 21346036.
12. Tasneem A, Aberle L, Ananth H, Chakraborty S, Chiswell K, McCourt BJ, Pietrobon R. The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS ONE 2012, 7(3):e33677. 10.1371/journal.pone.0033677, 3306288, 22438982.
13. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 2012, 307(17):1838-1847. 10.1001/jama.2012.3424, 22550198.
14. Hirsch B, Califf R, Cheng S. The state of the oncology clinical trials portfolio: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern Med 173(11):972-979.
15. Carpenter WR, Fortune-Greeley AK, Zullig LL, Lee S-Y, Weiner BJ. Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program. Contemp Clin Trials 2012, 33(1):46-54. 10.1016/j.cct.2011.09.007, 3253894, 21986391.
16. Gopal RK, Yamashita TE, Prochazka AV. Research without results: inadequate public reporting of clinical trial results. Contemp Clin Trials 2012, 33(3):486-491. 10.1016/j.cct.2012.02.001, 22342449.
17. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ 2012, 344:d7373. 10.1136/bmj.d7373, 22214756.